Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNF | P01375 | 10/20 | 0.42 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.35 |
| ▸ | EGFR | P00533 | 1/20 | 0.32 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.31 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.31 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.31 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18151454 | 1.00 | TNF (0.42) | TNFHTR2BGAATSHRADRA1A | |
| SCHEMBL18151601 | 0.87 | DRD2 (0.34) | TNFHTR2BGAATSHRADRA1A | |
| SCHEMBL18153418 | 0.87 | DRD2 (0.34) | TNFHTR2BGAATSHRADRA1A | |
| SCHEMBL16796880 | 0.86 | TNF (0.58) | TNFHTR2BGAATSHRADRA1A | |
| SCHEMBL16796926 | 0.86 | TNF (0.58) | TNFHTR2BGAATSHRADRA1A | |
| SCHEMBL16796877 | 0.86 | TNF (0.58) | TNFHTR2BGAATSHRADRA1A | |
| SCHEMBL16814797 | 0.85 | TNF (0.55) | TNFHTR2BGAATSHRADRA1A | |
| SCHEMBL18162350 | 0.85 | TNF (0.55) | TNFHTR2BGAATSHRADRA1A | |
| SCHEMBL16814794 | 0.85 | TNF (0.55) | TNFHTR2BGAATSHRADRA1A | |
| SCHEMBL18151018 | 0.83 | EPAS1 (0.34) | EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9856253-B2 | Tricyclic modulators of TNF signaling | ABBVIE, INC. (US) | 2018-01-02 | — | — | US | disclosed |
| US-20160304517-A1 | TRICYCLIC MODULATORS OF TNF SIGNALING | ABBVIE INC. | 2016-10-20 | — | — | US | disclosed |
| US-20160304517-A1 | TRICYCLIC MODULATORS OF TNF SIGNALING | ABBVIE INC. | 2016-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160304517-A1 | TRICYCLIC MODULATORS OF TNF SIGNALING | TNF, TNFRSF1A, CD40 | TNF 1/4885HTR2B 1712/4885GAA 3595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.